SEC Tracker
Get the app

Ocugen OCGN

Ocugen signs license deal with Celairis

Ocugen (OCGN) filed an 8-K with the SEC on Nov 10, 2026, 8:30 am ET. Source: the filing on SEC EDGAR.

Item 1.01 Enters material agreement, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Ocugen granted $6.1 million in fees and milestones
  2. Celairis gets exclusive rights in Asia-Pacific for OCU400
  3. Ocugen to receive royalties and 50% of gross profits from Celairis
  4. License agreement covers Australia, Singapore, New Zealand, and other Asian countries

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Ocugen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.